From time to time, the PBAC has recommended the listing of a new strength or new formulation of a given medicine for multiple diseases/conditions. A good example here is the 2006/3 PBAC recommendation to list a new formulation of etanercept (Enbrel) for use by certain patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis.  This recommendation has been entered in MAESTrO as a recommendation for patients with inflammatory disease. I am currently updating the database to ensure there is a discrete entry for each specific disease/condition.  You may notice these changes as recent entries. This will result in an increase in the number of ouctomes.  The submission count will remain unchanged.